Project: A paradigm shift in CU treatment: developing a first-in-class drug that regenerates colon epithelium

Acronym	EpicoliX (Reference Number: 114744)
Duration	01/05/2021 - 01/05/2024
Project Topic	We will develop a first-in-class drug for the treatment of Colitis Ulcerosa (CU) by stimulating differentiation of healthy colon epithelial cells to strengthen the intestinal barrier and prevent inflammation and ulcer formation. Here, we will select a lead compound with promising colon epithelial regeneration properties using a unique and novel organ-on-a chip model that recapitulates the diseased colon epithelilum and is to be developed in this project as well.
Network	Eurostars 2
Call	Eurostars Cut–off 14

Project partner

Number	Name	Role	Country
1	AlveoliX	Partner	Switzerland
2	EpiEndo Pharmaceuticals	Coordinator	Iceland